KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Income from Non-Controlling Interests: 2016-2024

Historic Income from Non-Controlling Interests for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $43.0 million.

  • Amneal Pharmaceuticals' Income from Non-Controlling Interests rose 32.32% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.7 million, marking a year-over-year increase of 36.19%. This contributed to the annual value of $43.0 million for FY2024, which is 21.94% up from last year.
  • As of FY2024, Amneal Pharmaceuticals' Income from Non-Controlling Interests stood at $43.0 million, which was up 21.94% from $35.3 million recorded in FY2023.
  • Amneal Pharmaceuticals' 5-year Income from Non-Controlling Interests high stood at $43.0 million for FY2024, and its period low was -$125.2 million during FY2022.
  • For the 3-year period, Amneal Pharmaceuticals' Income from Non-Controlling Interests averaged around -$15.7 million, with its median value being $35.3 million (2023).
  • Per our database at Business Quant, Amneal Pharmaceuticals' Income from Non-Controlling Interests skyrocketed by 142.46% in 2021 and then tumbled by 1,411.97% in 2022.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Income from Non-Controlling Interests stood at -$22.5 million in 2020, then spiked by 142.46% to $9.5 million in 2021, then slumped by 1,411.97% to -$125.2 million in 2022, then soared by 128.16% to $35.3 million in 2023, then grew by 21.94% to $43.0 million in 2024.